The Abbott/St. Jude Confirm RX implantable cardiac monitor (ICM) is the first ICM that is compatible with patients' smartphones to eliminate the need for a bedside base unit monitor to transfer data to physicians. Its FDA clearance was in October 2017.

November 3, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October, based on website analytics of the month’s 163,117 pageviews:

 

Top Cardiology Technology Articles

1. First Smartphone Compatible Insertable Cardiac Monitor Cleared by FDA

November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round of funding to $38 million. The round was led by MVM and Baxter Ventures. This funding will help VitalConnect in launching the VitalConnect Platform and VitalPatch wearable biosensor in hospitals and outpatient settings across the nation.

Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.

The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.

November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority. However, the second co-primary endpoint of post-procedure ischemic stroke/SE did achieve noninferiority.
The B. Braun Sequent Please drug-eluting balloon.
DARE trial results presented at TCT 2017 show drug coated balloons are equal to the Xience stent in treating restenosis.

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR. The study found the DEB was non-inferiority to the drug-eluting stent (DES).

November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure.

OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.

The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.

Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium, Oct. 29-Nov. 2 in Denver.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now